WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018002873) USE OF BGP15 TO STIMULATE MITOCHONDRIAL FUSION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/002873    International Application No.:    PCT/IB2017/053920
Publication Date: 04.01.2018 International Filing Date: 29.06.2017
IPC:
A61K 31/4545 (2006.01), A61P 9/04 (2006.01), A61P 11/00 (2006.01), A61P 27/02 (2006.01), A61P 25/00 (2006.01), A61P 25/02 (2006.01), A61P 43/00 (2006.01)
Applicants: N-GENE RESEARCH LABORATORIES, INC. [US/US]; 575 Madison Ave., 10th Floor New York, New York 10022 (US)
Inventors: SUMEGI, Balazs; (HU).
MANDL, Jozsef; (HU)
Priority Data:
16177514.3 01.07.2016 EP
Title (EN) USE OF BGP15 TO STIMULATE MITOCHONDRIAL FUSION
(FR) UTILISATION DE BGP15 POUR STIMULER LA FUSION MITOCHONDRIALE
Abstract: front page image
(EN)The present invention relates to the use of 0-(3-piperidino-2-hydroxy-l-propyl)- nicotinic amidoxime (BGP15), its tautomers, enantiomers and pharmaceutically acceptable salts thereof the treatment of diseases characterised at least in part by an excessive mitochondrial fragmentation activity or by a reduced mitochondrial fusion activity such as pulmonary fibrosis, age related macular degeneration, retinitis pigmentosa, heart failure with preserved ejection fraction, an inherited mtDNA depletion disorder (such as Alper's disease) or an inherited mtDNA deletion/mutation disorder (such as progressive external ophthalmoplegia, an ataxia-neuropathy spectrum disorder or mitochondrial neurogastrointestinal encephalomyopathy).
(FR)La présente invention concerne l'utilisation de l'amidoxime d'acide O-(3-pipéridino-2-hydroxy-1-propyl)-nicotinique (BGP15), ses tautomères, énantiomères et sels pharmaceutiquement acceptables de celui-ci pour le traitement de maladies caractérisées, au moins en partie, par une activité de fragmentation mitochondriale excessive ou par une activité de fusion mitochondriale réduite telle que la fibrose pulmonaire, de la dégénérescence maculaire liée à l'âge, de la rétinite pigmentaire, de l'insuffisance cardiaque avec fraction d'éjection conservée, d'un trouble héréditaire de déplétion d'ADNmt (tel que la maladie d'Alper) ou d'un trouble héréditaire de délétion/mutation d'ADNmt (tel que l'ophtalmoplégie externe progressive, un trouble du spectre de l'ataxie-neuropathie ou l'encéphalomyopathie neurogastro-intestinale mitochondriale).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)